ACTIVTRADES
20.11.2017 14:32:07 CET | Business Wire | Press release
ActivTrades , one of the world’s leading online Forex Brokers, has won the Le Fonti Forex Broker of the Year Award for the second year running.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005576/en/
A UK-regulated firm with offices in Europe and the Middle East, ActivTrades was selected as the winner by the editorial staff of over 120 journalists at Le Fonti, the international and independent media company and research centre.
Le Fonti credited the broker for “aiming to maximise its clients’ trading through a unique mix of superior value proposition, diverse product offering and stellar customer service ”. Le Fonti’s judges added that ActivTrades offers “some of the tightest spreads in the industry” and a “wide range of professional webinars ”.
ActivTrades specialises in providing industry-leading trading services in Forex and Contracts for Difference. As part of the company’s ongoing commitment to protect its global customer base, ActivTrades doubled its client insurance in September to £1 million, at no additional cost to the customer. This upgraded protection provides further assurances to clients with significantly larger investments.
Ricardo Evangelista , International Desk Manager at ActivTrades, said, “Our corporate values centre on the needs of our clients and it is hugely satisfying to have our efforts recognised for the second year running .”
“In times of rapid industry changes, we pride ourselves on going the extra mile for our clients. Our global customer base of over 50,000 is increasing year-on-year and in the third quarter of 2017 we recorded nearly 20,000 active traders. This is a testament to our ability to meet the market’s expectations as well as our ongoing commitment to expand and add value to our services .”
A highly anticipated celebration uniting the world’s leading corporate stars, the Le Fonti Awards recognises industry leaders in fields such as finance, banking, business and insurance.
ABOUT ACTIVTRADES
ActivTrades is a leading independent broker providing online trading services in Forex, Contracts for Difference (CFDs) and Spread Betting, operating since 2001. From its headquarters in London and its offices in Milan, Sofia and Dubai, ActivTrades serves an expansive global clientele who, over the years, have come to value its continuous innovation, excellent trading environment and effective risk management.
ActivTrades’ award-winning customer service is available 24 hours a day, Sunday evening through to Friday, and assists clients in 14 languages via phone, email and live chat.
A number of globally recognised awards have confirmed ActivTrades’ high standards over the years in areas like customer service, client protection and trading execution. The firm was also included in the Sunday Times Profit Track 100 list in 2017 for its large profit growth.
All leveraged products carry a high degree of risk to your capital and are not suitable for all investors.
ActivTrades PLC is authorised and regulated by the Financial Conduct Authority, registration number 434413.
The ActivTrades Excess of FSCS Insurance is subject to the Terms and Conditions of the policy wording; eligibility to the Financial Services Compensation Scheme depends on the nature and status of the claim.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171120005576/en/
Contact:
ActivTrades
PRESS CONTACT
RACHEL SAM, +44 (0)
207 6500 500
rsam@activtrades.com
or
LAURA
SALVAGE
lauras@pha-media.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom